Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

FOXA1: a promising prognostic marker in breast cancer.

Hu Q, Luo Z, Xu T, Zhang JY, Zhu Y, Chen WX, Zhong SL, Zhao JH, Tang JH.

Asian Pac J Cancer Prev. 2014;15(1):11-6. Review.

2.

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.

Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP.

Int J Cancer. 2007 Mar 1;120(5):1013-22.

3.

GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.

Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, Li XB.

Hum Pathol. 2016 Jan;47(1):26-31. doi: 10.1016/j.humpath.2015.09.015. Epub 2015 Sep 30.

PMID:
26527523
4.

Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Taketani K, Aishima S, Oda Y, Morita M, Maehara Y.

Breast Cancer. 2015 Sep;22(5):520-8. doi: 10.1007/s12282-013-0515-x. Epub 2014 Jan 11.

PMID:
24415069
5.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
6.

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.

PMID:
21984487
7.

FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.

Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.

Breast Cancer. 2015 May;22(3):308-16. doi: 10.1007/s12282-013-0482-2. Epub 2013 Jun 16.

PMID:
23771556
8.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
9.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

10.

Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis.

Shou J, Lai Y, Xu J, Huang J.

Breast. 2016 Jun;27:35-43. doi: 10.1016/j.breast.2016.02.009. Epub 2016 Mar 21. Review.

PMID:
27212698
11.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
12.

FOXA1 as a therapeutic target for breast cancer.

Nakshatri H, Badve S.

Expert Opin Ther Targets. 2007 Apr;11(4):507-14. Review.

PMID:
17373880
13.

The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers.

Li X, Chen S, Sun T, Xu Y, Chen Y, Liu Y, Xiang R, Li N.

Clin Lab. 2014;60(6):909-18.

PMID:
25016694
14.

FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.

Xu C, Wei Q, Guo J, Zhou JC, Mei J, Jiang ZN, Shen JG, Wang LB.

Ann Surg Oncol. 2015;22(6):2034-9. doi: 10.1245/s10434-014-4313-2. Epub 2015 Feb 24.

PMID:
25707489
15.

FoxA1 as a lineage-specific oncogene in luminal type breast cancer.

Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, Semba K, Watanabe S.

Biochem Biophys Res Commun. 2008 Jan 25;365(4):711-7. Epub 2007 Nov 26.

PMID:
18039470
16.

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.

Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4.

PMID:
18538561
17.

[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].

Liu N, Niu Y, Wang SL, Yu Q, Zhang RJ, Liu TJ.

Zhonghua Yi Xue Za Zhi. 2010 May 25;90(20):1403-7. Chinese.

PMID:
20646630
18.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

19.

Survivin--prognostic tumor biomarker in human neoplasms--review.

Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek V, Ruchała M.

Ginekol Pol. 2012 Jul;83(7):537-40. Review.

PMID:
22880480
20.

[FOXA1 expression in luminal-type breast cancer].

Tokunaga E, Hisamatsu Y, Maehara Y.

Nihon Rinsho. 2012 Sep;70 Suppl 7:438-42. Japanese. No abstract available.

PMID:
23350438

Supplemental Content

Support Center